Biogen Idec, Vernalis ally in Parkinson's disease; terminated
Drug development company Vernalis PLC (focuses on neuroscience and oncology) licensed Biogen Idec (therapeutics for disorders in oncology, neurology, dermatology, and rheumatology) exclusive worldwide rights to develop and commercialize its lead compound V2006 (formerly VR 2006), an adenosine A2A receptor antagonist in Phase I for Parkinson's disease (PD).
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.